Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer

British Journal of Cancer

Volumn 104, Issue 7, 2011, Pages 1071-1078

  Stemmler, H J ^a   Digioia, D ^a   Freier, W ^b   Tessen, H W ^c   Gitsch, G ^d   Jonat, W ^e   Brugger, W ^f   Kettner, E ^g   Abenhardt, W ^h   Tesch, H ⁱ   Hurtz, H J ^j   Rosel S ^k   Brudler, O ^l   Heinemann, V ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Department of Hematology   (Germany)

^c Oncological Practice   (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

^e UNIVERSITY OF KIEL   (Germany)

^f Hochsch F Technik und Wirtschaft   (Germany)

^g University Clinic Magdeburg   (Germany)

^h Oncological Practice   (Germany)

ⁱ Oncological Practice   (Germany)

^j Oncological Practice   (Germany)

^k Oncological Practice   (Germany)

^l Hematology and Oncology Practice   (Germany)

more..

Author keywords

anthracycline resistance; capecitabine; cisplatin; gemcitabine; metastatic breast cancer; vinorelbine

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTIEMETIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CAPECITABINE; CISPLATIN; CORTICOSTEROID; FUROSEMIDE; GEMCITABINE; NAVELBINE; SEROTONIN 3 ANTAGONIST;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BONE PAIN; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DYSPNEA; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; METASTASIS; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; SKIN DISEASE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CISPLATIN; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; VINBLASTINE;

EID: 79953219391     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.86     Document Type: Article

References (53)

1. Achanta G, Pelicano H, Feng L, Plunkett W, Huang P (2001) Interaction of p53 and DNA-PK in response to nucleoside analogues: potential role as a sensor complex for DNA damage. Cancer Res 61: 8723-8729 (Pubitemid 34013883)
2. Ahn JH, Kim SB, Kim TW, Ahn SH, Kim SM, Park JM, Lee JS, Kang YK, Kim WK (2004) Capecitabine and vinorelbine in patients with metastatic breast cancer previously treated with anthracycline and taxane. J Korean Med Sci 19: 547-553
3. Ajani JA, Welch SR, Raber MN, Fields WS, Krakoff IH (1990) Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest 8: 147-159 (Pubitemid 20350387)
4. Alauddin A, Shaharyar A (2005) Gemcitabine and cisplatin combination chemotherapy as first-line treatment in patients with metastatic breast cancer. J Clin Oncol, ASCO Annu Meeting Proc (Post-Meeting Edition) 23: abstract 713
5. Andres R, Mayordomo JI, Lara R, Lastra R, Ortega E, Polo E, Lambea J, Isla D, Saenz-Cusi A, Escudero P, Tres A (2005) Gemcitabine/ capecitabine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes. Clin Breast Cancer 6: 158-162 (Pubitemid 40975612)
6. Batista N, Perez-Manga G, Constenla M, Ruiz A, Carabantes F, Castellanos J, Gonzalez Baron M, Villman K, Soderberg M, Ahlgren J, Casinello J, Regueiro P, Murias A (2004) Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/meta-static breast cancer. Br J Cancer 90: 1740-1746 (Pubitemid 38725644)
7. Blackstein M, Vogel CL, Ambinder R, Cowan J, Iglesias J, Melemed A (2002) Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial. Oncology 62: 2-8 (Pubitemid 34124219)
8. Brodowicz T, Kostler WJ, Moslinger R, Tomek S, Vaclavik I, Herscovici V, Wiltschke C, Steger GG, Wein W, Seifert M, Kubista E, Zielinski CC (2000) Single-agent gemcitabine as second- and third-line treatment in metastatic breast cancer. Breast 9: 338-342
9. Burch PA, Mailliard JA, Hillman DW, Perez EA, Krook JE, Rowland KM, Veeder MH, Cannon MW, Ingle JN (2005) Phase II study of gemcitabine plus cisplatin in patients with metastatic breast cancer: a North Central Cancer Treatment Group Trial. Am J Clin Oncol 28: 195-200
10. Campos LT, Alvarez RH, Sanford DB (2001) Gemcitabine and Capecitabine in advanced pancreatic cancer and solid tumors: a sigle institution experience. Proc Am Soc Clin Oncol 20: abstract #2315
11. Chew HK, Doroshow JH, Frankel P, Margolin KA, Somlo G, Lenz HJ, Gordon M, Zhang W, Yang D, Russell C, Spicer D, Synold T, Bayer R, Hantel A, Stiff PJ, Tetef ML, Gandara DR, Albain KS (2009) Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer. J Clin Oncol 27: 2163-2169
12. Chitapanarux I, Lorvidhaya V, Kamnerdsupaphon P, Tharavichitkul E, Trakultivakorn H, Somwangprasert A, Sumitsawan S, Srisukho S, Watcharachan K, Sukthomya V (2006) Gemcitabine plus cisplatin (GC): a salvage regimen for advanced breast cancer patients who have failed anthracycline and/or taxane therapy. Gan To Kagaku Ryoho 33: 761-766
13. Ciruelos EM, Cortes J, Cortes-Funes H, Mayordomo JI, Bermejo B, Ojeda B, Garcia E, Rodriguez CA, Munoz M, Gomez P, Manso L, Andres R, Lluch A, Saura C, Mendiola C, Baselga J (2009) Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: a multicenter phase II study (SOLTI 0301 trial). Ann Oncol 21(7): 1442-1447
14. Degardin M, Bonneterre J, Hecquet B, Pion JM, Adenis A, Horner D, Demaille A (1994) Vinorelbine (navelbine) as a salvage treatment for advanced breast cancer. Ann Oncol 5: 423-426 (Pubitemid 24159646)
15. Demiray M, Evrensel T, Kanat O, Kurt E, Arslan M, Gokgoz S, Tolunay S, Manavoglu O (2006) Open labeled phase II observation study of gemcitabine plus cisplatin plus trastuzumab (GCT) in metastatic breast cancer patients with prior anthracyclines and taxanes exposures: Preliminary results. J Clin Oncol, ASCO Ann Meeting Proc (Post-Meeting Edition) 24: abstract 10720
16. Fuentes H, Calderillo G, Alexander F, Ramirez M, Avila E, Perez L, Aguirre G, Onate-Ocana LF, Gallardo D, Otero J (2006) Phase II study of gemcitabine plus cisplatin in metastatic breast cancer. Anticancer Drugs 17: 565-570 (Pubitemid 44309973)
17. Gregory RK, Smith IE (2000) Vinorelbine-a clinical review. Br J Cancer 82: 1907-1913
18. Haider K, Kornek GV, Kwasny W, Weinlander G, Valencak J, Lang F, Puribauer F, Kovats E, Depisch D, Scheithauer W (1999) Treatment of advanced breast cancer with gemcitabine and vinorelbine plus human granulocyte colony-stimulating factor. Breast Cancer Res Treat 55: 203-211 (Pubitemid 29425573)
19. Heinemann V (2003) Role of gemcitabine in the treatment of advanced and metastatic breast cancer. Oncology 64: 191-206 (Pubitemid 36438803)
20. Heinemann V (2005) Gemcitabine in metastatic breast cancer. Expert Rev Anticancer Ther 5: 429-443 (Pubitemid 40894977)
21. Heinemann V, Stemmler HJ, Wohlrab A, Bosse D, Losem C, Kahlert S, Rauthe G (2006) High efficacy of gemcitabine and cisplatin in patients with predominantly anthracycline- and taxane-pretreated metastatic breast cancer. Cancer Chemother Pharmacol 57: 640-646 (Pubitemid 43237849)
22. Jones S, Winer E, Vogel C, Laufman L, Hutchins L, O'Rourke M, Lembersky B, Budman D, Bigley J, Hohneker J (1995) Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol 13: 2567-2574
23. Kaplan EL, Meier P (1959) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481
24. Kim JH, Oh SY, Kwon HC, Lee S, Kim SH, Kim DC, Lee JH, Lee HS, Cho SH, Kim HJ (2008) Phase II study of gemcitabine plus cisplatin in patients with anthracycline- and taxane- pretreated metastatic breast cancer. Cancer Res Treat 40: 101-105
25. Kolaric K, Vukas D (1991) Carboplatin activity in untreated metastatic breast cancer patients-results of a phase II study. Cancer Chemother Pharmacol 27: 409-412
26. Koshy N, Quispe D, Shi R, Mansour R, Burton GV (2010) Cisplatin-gemcitabine therapy in metastatic breast cancer: Improved outcome in triple negative breast cancer patients compared to non-triple negative patients. Breast 19: 246-248
27. Laessig D, Stemmler HJ, Vehling-Kaiser U, Fasching PA, Melchert F, Kolbl H, Stauch M, Maubach P, Scharl A, Morack G, Meerpohl H, Weber B, Kalischefski B, Heinemann V (2007) Gemcitabine and carboplatin in intensively pretreated patients with metastatic breast cancer. Oncology 73: 407-414 (Pubitemid 351862038)
28. Lee SH, Lee J, Park J, Park SH, Lee KE, Lee SI, Nam E, Park JO, Kim K, Jung CW, Park YS, Yoon SS, Kang WK, Lee MH, Park K, Im YH (2004) Capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Med Oncol 21: 223-231 (Pubitemid 39469762)
29. Loesch D, Asmar L, McIntyre K, Doane L, Monticelli M, Paul D, Vukelja S, Orlando M, Vaughn LG, Zhan F, Boehm KA, O'Shaughnessy JA (2008) Phase II trial of gemcitabine/carboplatin (plus trastuzumab in HER2-positive disease) in patients with metastatic breast cancer. Clin Breast Cancer 8: 178-186 (Pubitemid 351655933)
30. Malmstrom A, Hansen J, Malmberg L, Carlsson L, Svensson JH, Ahlgren J, Ahlin C, Jansson T, Westberg R (2010) Gemcitabine and capecitabine in combination for advanced anthracycline and taxane pre-treated breast cancer patients: A phase II study. Acta Oncol 49: 35-41
31. Modi S, Currie VE, Seidman AD, Bach AM, Panageas KS, Theodoulou M, Moasser MM, D'Andrea GM, Lake DE, Choi J, Norton L, Hudis CA (2005) A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane. Clin Breast Cancer 6: 55-60 (Pubitemid 40872947)
32. Mohran TZ (2004) Gemcitabine and cisplatin combination chemotherapy as a first-line treatment in patients with metastatic breast cancer. J Egypt Natl Canc Inst 16: 8-14
33. Moura GL, Pasquini R, Frare A, Vianna K, Albini L, Padilha S (2007) Gemcitabine and cisplatin in metastatic breast cancer. J Clin Oncol, ASCO Annu Meeting Proc (Post-Meeting Edition) 25: abstract 1084
34. Nagourney RA, Flam M, Link J, Hager S, Blitzer J, Lyons W, Sommers BL, Evans S (2008) Carboplatin plus gemcitabine repeating doublet therapy in recurrent breast cancer. Clin Breast Cancer 8: 432-435
35. Nagourney RA, Link J, Sommers B, Lyons W, Blitzer J, Hager S, Flam M (2004) Carboplatin & gemcitabine repeating doublet in recurrent breast cancer. J Clin Oncol, 2004 ASCO Annu Meeting Proc (Post-Meeting Edition) 22: 851
36. Nasr FL, Chahine GY, Kattan JG, Farhat FS, Mokaddem WT, Tueni EA, Dagher JE, Ghosn MG (2004) Gemcitabine plus carboplatin combination therapy as second-line treatment in patients with relapsed breast cancer. Clin Breast Cancer 5: 117-122: discussion 123-114 (Pubitemid 39029202)
37. Nicolaides C, Dimopoulos MA, Samantas E, Bafaloukos D, Kalofonos C, Fountzilas G, Razi E, Kosmidis P, Pavlidis N (2000) Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer progressing after first-line taxane-based chemotherapy: a phase II study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 11: 873-875
38. Oshaughnessy JA, Blum J, Moiseyenko V, Jones SE, Miles D, Bell D, Rosso R, Mauriac L, Osterwalder B, Burger HU, Laws S (2001) Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 12: 1247-1254 (Pubitemid 32994752)
39. Park IH, Ro J, Lee KS, Kim SN, Yun YH, Nam BH (2009) Phase II study of gemcitabine in combination with vinorelbine versus gemcitabine followed by vinorelbine for metastatic breast cancer. Invest New Drugs 28(5): 659-669
40. Peters GJ, Bergman AM, Ruiz Van Haperen VW, Veerman G, Kuiper CM, Braakhuis BJ (1995) Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 22: 72-79
41. Schilsky RL, Bertucci D, Vogelzang NJ (2001) A dose escalating study of capecitabine plus gemcitabine in patients with advanced cancer. Proc Am Soc Clin Oncol 20: abstract 369
42. Seo JH, Oh SC, Choi CW, Kim BS, Shin SW, Kim YH, Kim JS, Kim AR, Lee JB, Koo BH (2007) Phase II study of a gemcitabine and cisplatin combination regimen in taxane resistant metastatic breast cancer. Cancer Chemother Pharmacol 59: 269-274 (Pubitemid 44885156)
43. Shehata S, Saad E, Goda Y, El-Mesidi S, Koheil H, Elzawhri H, Kandeel A, Abdelhamid T, Zaki M, Meshref M (2010) A phase II study of gemcitabine combined with vinorelbine as first-line chemotherapy for metastatic breast cancer. Hematol Oncol Stem Cell Ther 3: 1-6
44. Silva JA, Perez Michel LM, Gallardo Rincon D (2004) Gemcitabine plus carboplatin in recurrent and advanced breast cancer: A phase II trial. J Clin Oncol, ASCO Annu Meeting Proc (Post-Meeting Edition) 22: 877
45. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10: 1-10 (Pubitemid 19099520)
46. Somali I, Alacacioglu A, Tarhan MO, Meydan N, Erten C, Usalp S, Yilmaz U (2009) Cisplatin plus gemcitabine chemotherapy in taxane/anthra-cycline- resistant metastatic breast cancer. Chemotherapy 55: 155-160
47. Spielmann M, Llombart-Cussac A, Kalla S, Espie M, Namer M, Ferrero JM, Dieras V, Fumoleau P, Cuvier C, Perrocheau G, Ponzio A, Kayitalire L, Pouillart P (2001) Single-agent gemcitabine is active in previously treated metastatic breast cancer. Oncology 60: 303-307 (Pubitemid 32623443)
48. Stathopoulos GP, Rigatos SK, Pergantas N, Tsavdarides D, Athanasiadis I, Malamos NA, Stathopoulos JG (2002) Phase II trial of biweekly administration of vinorelbine and gemcitabine in pretreated advanced breast cancer. J Clin Oncol 20: 37-41 (Pubitemid 34032593)
49. Stemmler HJ, Kahlert S, Brudler O, Beha M, Muller S, Stauch B, Heinemann V (2005) High efficacy of gemcitabine and cisplatin plus trastuzumab in patients with HER2-overexpressing metastatic breast cancer: a phase II study. Clin Oncol (R Coll Radiol) 17: 630-635 (Pubitemid 41700328)
50. Valenza R, Leonardi V, Gebbia V, Agostara B (2000) Gemcitabine and vinorelbine in pretreated advanced breast cancer: a pilot study. Ann Oncol 11: 495-496 (Pubitemid 30333558)
51. Van Moorsel CJ, Veerman G, Bergman AM, Guechev A, Vermorken JB, Postmus PE, Peters GJ (1997) Combination chemotherapy studies with gemcitabine. Semin Oncol 24(2 Suppl 7): S7-17-S17-23 (Review)
52. Wist EA, Sommer HH, Ostenstad B, Risberg T, Bremnes Y, Mjaaland I (2004) Oral capecitabine in anthracycline- and taxane-pretreated advanced/metastatic breast cancer. Acta Oncol 43: 186-189 (Pubitemid 38478906)
53. Yardley DA, Peacock N, Shipley D, Waterhause D, Landgdon R, Simons L, Thomas S, Hainsworth JD, Spigel DR, Burris HA (2006) Phase II trial of gemcitabine and carboplatin, plus trastuzumab in HER2+ patients as first line therapy in metastatic breast cancer. J Clin Oncol, ASCO Annu Meeting Proc (Post-Meeting Edition) 24: abstract no. 10590